# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Erasca intends to use the net proceeds from this offering, together with its existing cash, cash equivalents and marketable sec...
Pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001 are potent, oral inhibitors with potential best-in-class prof...
The Company will deprioritize the ERAS-007 program as the Company believes the clinical efficacy data from the HERKULES-3 clini...
https://www.sec.gov/ix?doc=/Archives/edgar/data/1761918/000119312524140591/d832290d8k.htm
HC Wainwright & Co. analyst Andres Maldonado reiterates Erasca (NASDAQ:ERAS) with a Buy and maintains $8 price target.
Erasca (NASDAQ:ERAS) reported quarterly losses of $(0.23) per share which missed the analyst consensus estimate of $(0.22) by 4...
Goldman Sachs analyst Chris Shibutani maintains Erasca (NASDAQ:ERAS) with a Buy and raises the price target from $6 to $7.